Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

8.01

-0.25 (-3.03%)

At close: Aug 28, 2026, 4:00 PM EDT

8.03

+0.02 (0.25%)

After-hours: Aug 28, 2026, 7:52 PM EDT

Iovance Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	110.77	163.08	115.69	114.89	231.73	78.23
Short-Term Investments	186.91	133.9	208.09	164.98	240.11	426.18
Cash & Short-Term Investments	297.67	296.98	323.78	279.87	471.85	504.41
Cash Growth	-1.17%	-8.28%	15.69%	-40.69%	-6.46%	-19.86%
Receivables	102.12	82.45	69.34	0.15	-	-
Inventory	55.59	51.68	51.52	10.37	-	-
Prepaid Expenses	8.87	11.58	12.38	17.46	7.27	3.55
Total Current Assets	464.26	442.69	457.02	307.85	479.12	507.96
Property, Plant & Equipment	174.94	177.01	164.28	176.55	178.25	169.92
Long-Term Investments	-	-	-	-	-	91.59
Other Intangible Assets	263.89	279.32	282.4	229.26	-	-
Other Long-Term Assets	12.44	14.15	6.73	66.7	6.62	7.87
Total Assets	915.53	913.17	910.43	780.35	663.98	777.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	26.21	22.16	27.51	33.12	26.6	27.38
Accrued Expenses	74.62	104.71	75.19	66.97	45.79	51.91
Current Portion of Long-Term Debt	-	1	-	-	-	-
Current Portion of Leases	2.67	4.04	12.9	7.78	12.59	5.06
Other Current Liabilities	3.35	6.45	6.75	2.44	6.51	4.86
Total Current Liabilities	106.85	138.36	122.34	110.31	91.49	89.2
Long-Term Debt	-	-	1	1	1	1
Long-Term Leases	43.33	44.4	44.37	67.09	71.86	65.47
Long-Term Deferred Tax Liabilities	29.31	31.83	32.32	17.35	-	-
Total Liabilities	179.49	214.59	200.02	195.74	164.34	155.67

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-In Capital	3,625	3,458	3,096	2,594	2,069	1,795
Retained Earnings	-2,902	-2,776	-2,385	-2,012	-1,568	-1,172
Comprehensive Income & Other	13.08	16.44	-1.05	2.53	-0.9	-0.6
Total Common Equity	736.04	698.58	710.4	584.61	499.64	621.66
Shareholders' Equity	736.05	698.58	710.41	584.61	499.64	621.66
Total Liabilities & Equity	915.53	913.17	910.43	780.35	663.98	777.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	46	49.44	58.26	75.86	85.45	71.53
Net Cash (Debt)	251.67	247.54	265.52	204.01	386.4	432.88
Net Cash Growth	1.47%	-6.77%	30.15%	-47.20%	-10.74%	-25.08%
Net Cash Per Share	0.61	0.69	0.92	0.87	2.43	2.82
Filing Date Shares Outstanding	452.97	411.96	327.88	279.31	224.24	157.17
Total Common Shares Outstanding	452.97	411.94	305.25	256.14	187.81	157
Working Capital	357.41	304.33	334.68	197.54	387.63	418.76
Book Value Per Share	1.62	1.70	2.33	2.28	2.66	3.96
Tangible Book Value	472.15	419.26	428	355.35	499.64	621.66
Tangible Book Value Per Share	1.04	1.02	1.40	1.39	2.66	3.96
Machinery	44.89	45.34	34.28	33.27	31.79	14.87
Construction In Progress	5.56	35.65	34.94	24.1	9.12	35.78
Leasehold Improvements	128.89	90.39	67.38	76.8	74.31	57.82

SEC Filings: 10-K · 10-Q